Wall Street brokerages expect Recro Pharma Inc (NASDAQ:REPH) to post $16.77 million in sales for the current fiscal quarter, according to Zacks. Four analysts have made estimates for Recro Pharma’s earnings, with the lowest sales estimate coming in at $15.32 million and the highest estimate coming in at $18.00 million. Recro Pharma reported sales of $17.11 million during the same quarter last year, which indicates a negative year over year growth rate of 2%. The firm is expected to report its next earnings results on Thursday, November 8th.
According to Zacks, analysts expect that Recro Pharma will report full year sales of $72.73 million for the current fiscal year, with estimates ranging from $71.00 million to $73.43 million. For the next year, analysts expect that the company will post sales of $77.97 million, with estimates ranging from $71.00 million to $88.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that cover Recro Pharma.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.72. Recro Pharma had a negative return on equity of 144.84% and a negative net margin of 75.19%. The firm had revenue of $21.74 million for the quarter, compared to analysts’ expectations of $16.81 million.
A number of brokerages have recently commented on REPH. ValuEngine raised Recro Pharma from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 19th. Janney Montgomery Scott set a $13.00 price objective on Recro Pharma and gave the stock a “buy” rating in a report on Monday, October 1st. Finally, Oppenheimer set a $18.00 price objective on Recro Pharma and gave the stock a “buy” rating in a report on Wednesday, September 5th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $12.96.
Shares of NASDAQ REPH traded down $0.38 during trading on Friday, reaching $6.84. 173,742 shares of the stock traded hands, compared to its average volume of 260,378. Recro Pharma has a 52-week low of $4.78 and a 52-week high of $13.05. The company has a debt-to-equity ratio of 2.22, a current ratio of 1.59 and a quick ratio of 1.42. The stock has a market capitalization of $149.79 million, a PE ratio of -3.44 and a beta of -0.82.
Institutional investors and hedge funds have recently modified their holdings of the stock. JPMorgan Chase & Co. lifted its holdings in Recro Pharma by 211.8% during the 1st quarter. JPMorgan Chase & Co. now owns 98,751 shares of the specialty pharmaceutical company’s stock worth $1,087,000 after purchasing an additional 67,078 shares in the last quarter. Cadence Capital Management LLC lifted its holdings in Recro Pharma by 6.6% during the 2nd quarter. Cadence Capital Management LLC now owns 151,323 shares of the specialty pharmaceutical company’s stock worth $760,000 after purchasing an additional 9,381 shares in the last quarter. Newtyn Management LLC purchased a new stake in Recro Pharma during the 2nd quarter worth about $4,456,000. GSA Capital Partners LLP purchased a new stake in Recro Pharma during the 2nd quarter worth about $206,000. Finally, Orbimed Advisors LLC purchased a new stake in Recro Pharma during the 2nd quarter worth about $539,000. 55.03% of the stock is currently owned by institutional investors and hedge funds.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Read More: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.